Info
PI3K-mTOR in Cancer and Cancer Therapy / / edited by Nandini Dey, Pradip De, Brian Leyland-Jones
| PI3K-mTOR in Cancer and Cancer Therapy / / edited by Nandini Dey, Pradip De, Brian Leyland-Jones |
| Edizione | [1st ed. 2016.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Humana, , 2016 |
| Descrizione fisica | 1 online resource (XXIV, 294 p. 31 illus. in color.) |
| Disciplina | 616.994071 |
| Collana | Cancer Drug Discovery and Development |
| Soggetto topico |
Cancer - Research
Molecular biology Drug resistance Cancer Research Molecular Medicine Drug Resistance |
| ISBN | 3-319-34211-8 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | PI3K-Akt-mTOR Signaling in Cancer and Cancer Therapeutics -- Part 1: PI3K-mTOR Pathway in Cancers -- The mTOR Complexes in Cancer Cell Metabolism -- PI3K-AKT-mTOR Pathway Co-operates with the DNA Damage Repair Pathway: Carcinogenesis in Triple Negative Breast Cancers and Beyond -- The AKT-mTOR Signaling Pathway for Drug Response Prediction and Prognostic Signatures -- Resistance to PI3K Pathway Inhibition -- Part 2: PI3K-mTOR Pathway in Cancer Medicine -- Combination Therapies Targeting the PI3K/AKT/mTOR Pathways -- Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma -- HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies -- The PI3K-mTOR Pathway in Prostate Cancer: Biological Significance and Therapeutic Opportunities. |
| Record Nr. | UNINA-9910254558503321 |
| Cham : , : Springer International Publishing : , : Imprint : Humana, , 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Precision Medicine in Solid Tumors
| Precision Medicine in Solid Tumors |
| Autore | Dey Nandini |
| Pubbl/distr/stampa | Basel, : MDPI Books, 2022 |
| Descrizione fisica | 1 electronic resource (304 p.) |
| Soggetto topico |
Medicine
Oncology |
| Soggetto non controllato |
pediatric tumors
tumor mutational burden TMB whole-exome sequencing gene panel sequencing immune checkpoint inhibitors glioblastoma prognosis overall survival extent of resection random forest Decision tree personalized precision oncology circulating free DNA liquid biopsy epidermal growth factor receptor tyrosine kinase inhibitor osimertinib comprehensive genomic profiling molecular genotyping intratumor heterogeneity multiple biopsies tumor evolution clonality classification strategic therapeutic intervention thymoma driver mutation sequencing molecular barcoding EGFR mutation EGFR-TKI cfDNA NGS digital enrichment next-generation sequencing solid cancer universal health-care system precision medicine presumed germline findings clinical guideline non-small cell lung cancer outcome adjuvant chemotherapy anaplastic lymphoma receptor tyrosine kinase HNSCC ctDNA tDNA DDR genes PARP inhibitors new drug development next-generation sequencing (NGS) open data regulatory reform tumor profiling test triple-negative breast cancer (TNBC) breast cancer targeted therapy TNBC subtypes immunotherapy cancer screening smoking electronic records PD-L1 cancer-associated fibroblasts resistance chemotherapy CTC immunocytochemistry parallel double-detection laboratory-friendly |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910595078103321 |
Dey Nandini
|
||
| Basel, : MDPI Books, 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||